In-hospital metabolite changes in infective endocarditis—a longitudinal 1H NMR-based study

Klein, Christine Falk; Holle, Sarah Louise Kjølhede; Andersen, Malene Højgaard; Pedersen, Anders; Bundgaard, Henning; Iversen, Kasper; Malmendal, Anders

doi:10.1007/s10096-019-03586-z

Cited by 4 publications

(7 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of note, levels of several serum metabolites also rose in the control group [16]. In a recent study, blood samples drawn early (0 -2 days) and late (25 days +) during treatment of infective endocarditis with any of several antibiotics, showed a lowering of several amino acids (L-tyrosine, L-valine, L-leucine, L-isoleucine) and other chemicals (glucose, mannose, unspecified polyol) [17]. Overall, the heterogeneity of antibiotics, duration of treatment, and panels of evaluated chemicals in these studies does not justify generalized conclusions.…”

Section: Human Studies Of Antibiotic Effectsmentioning

confidence: 89%

“…A PubMed Search (initial search terms: [(serum OR plasma OR blood) AND antibiotic AND metabolome AND human]) yielded only 5 heterogeneous human serum studies of antibiotic effects [14][15][16][17]. An 8-week treatment of patients (n = 20) with cirrhosis and minimal hepatic encephalopathy with rifaximin, a poorly absorbed antibiotic with minimal effect on the GMB [18], elevated serum levels of several saturated as well as unsaturated fatty acids [72].…”

Section: Human Studies Of Antibiotic Effectsmentioning

confidence: 99%

“…An alternative approach is to evaluate antibiotic regimens that in rodent models selectively suppress certain microbial taxa [8][9][10][11] or eliminate most of the GMB, thus generating a pseudo-GF status [12]. Although it has been more than 65 years since antibiotic treatment was first observed to lower excretion of volatile phenols in man [13], a current literature search identified only 5 studies of antibiotic effects on the human serum metabolome [14][15][16][17][18]. Given the high and rising global use of antibiotics [19], the paucity of metabolomic studies in antibiotic-exposed humans constitutes a striking knowledge gap that must be acknowledged, explained, and resolved.…”

Section: Introductionmentioning

confidence: 99%

“…The lower variance of chemical levels in serum [36] relative to those in urine [35] or feces [38] should make the human serum metabolome particularly useful for studying antibiotic effects. The small number of such reports [14][15][16][17][18] may be due to both technical and statistical barriers. Identification and quantification of chemicals using a targeted analytic approach requires having authentic standards and generating calibration curves for each analyte of interest.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Changes in the Serum Metabolome of Patients Treated With Broad-Spectrum Antibiotics

Jaskiw

Obrenovich

Kundrapu

et al. 2020

PAI

View full text Add to dashboard Cite

Background: The gut microbiome (GMB) generates numerous small chemicals that can be absorbed by the host and variously biotransformed, incorporated, or excreted. The resulting metabolome can provide information about the state of the GMB, of the host, and of their relationship. Exploiting this information in the service of biomarker development is contingent on knowing the GMB-sensitivity of the individual chemicals comprising the metabolome. In this regard, human studies have lagged far behind animal studies. Accordingly, we tested the hypothesis that serum levels of chemicals unequivocally demonstrated to be GMB-sensitive in rodent models would also be affected in a clinical patient sample treated with broad spectrum antibiotics.Methods: We collected serum samples from 20 hospitalized patients before, during, and after treatment with broad-spectrum antibiotics. We also collected samples from 5 control patients admitted to the hospital but not prescribed antibiotics. We submitted the samples for a non-targeted metabolomic analysis and then focused on chemicals known to be affected both by germ-free status and by antibiotic treatment in the mouse and/or rat.Results: Putative identification was obtained for 499 chemicals in human serum. An aggregate analysis did not show any time x treatment interactions. However, our literature search identified 10 serum chemicals affected both by germ-free status and antibiotic treatment in the mouse or rat. Six of those chemicals were measured in our patient samples and additionally met criteria for inclusion in a focused analysis. Serum levels of 5 chemicals (p-cresol sulfate, phenol sulfate, hippurate, indole propionate, and indoxyl sulfate) declined significantly in our group of antibiotic-treated patients but did not change in our patient control group.Conclusions: Broad-spectrum antibiotic treatment in patients lowered serum levels of selected chemicals previously demonstrated to be GMB-sensitive in rodent models. Interestingly, all those chemicals are known to be uremic solutes that can be derived from aromatic amino acids (L-phenylalanine, L-tyrosine, or L-tryptophan) by anaerobic bacteria, particularly Clostridial species. We conclude that judiciously selected serum chemicals can reliably detect antibiotic-induced suppression of the GMB in man and thus facilitate further metabolome-based biomarker development.

show abstract

Section: Human Studies Of Antibiotic Effectsmentioning

confidence: 89%

Section: Human Studies Of Antibiotic Effectsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Changes in the Serum Metabolome of Patients Treated With Broad-Spectrum Antibiotics

Jaskiw

Obrenovich

Kundrapu

et al. 2020

PAI

View full text Add to dashboard Cite

show abstract

“…EDTA blood samples were collected from each patient and centrifuged at 3.900×g for 10 min (as described in (20)). The supernatant, plasma, was aliquoted, immediately frozen and kept at -80 °C until further analyses.…”

Section: Collection and Storage Of Samplesmentioning

confidence: 99%

Plasma levels of glucagon but not GLP-1 are elevated in response to inflammation in humans

Modrzynska

Klein

Iversen

et al. 2021

Endocrine Connections

Self Cite

View full text Add to dashboard Cite

Objective: Glucagon and glucagon-like peptide-1 (GLP-1) originate from the common precursor, proglucagon, and their plasma concentrations have been reported to be increased during inflammatory conditions. Increased blood glucose levels are frequently observed in septic patients, and therefore we hypothesized that glucagon, but not GLP-1, is increased in individuals with inflammation. Design: Prospective longitudinal cohort study. Materials and Methods: We measured glucagon and GLP-1 in plasma sampled consecutively in three cohorts consisting of patients with infective endocarditis (n=16), urosepsis (n=28) and post-operative inflammation following percutaneous aortic valve implantation or thoracic endovascular aortic repair (n=5). Correlations between C-Reactive Protein (CRP), a marker of systemic inflammation, and glucagon and GLP-1 concentrations were investigated. Additionally, glucagon and GLP-1 concentrations were measured after a bolus infusion of lipopolysaccharide (LPS, 1ng/kg) in nine healthy young males. Results: Glucagon and CRP were positively and significantly correlated (r=0.27; P=0.0003), whereas no significant association between GLP-1 and CRP was found (r=0.08, P=0.30). LPS infusion resulted in acute systemic inflammation reflected by increased temperature, pulse, tumor necrosis factor-α (TNFα), interleukin-6 (IL-6) and concomitantly increased concentrations of glucagon (P<0.05) but not GLP-1. Conclusions :Systemic inflammation caused by bacterial infections or developed as a non-infected condition is associated with increased plasma concentration of glucagon, but not GLP-1. Hyperglucagonemia may contribute to the impaired glucose control in patients with systemic inflammatory diseases.

show abstract

Dental Intervention and the Risks of Bacterial Endocarditis in the Hospital Environment

Aragão¹,

Souza²,

Pereira³

et al. 2023

JHS

View full text Add to dashboard Cite

The oral cavity is a very large entrance for various periodontal diseases and the development of systemic pathologies. Therefore, not taking proper care of oral health can lead to the development of much more than inflammation, and this becomes even more worrying when it involves patients hospitalized in the hospital environment with valvular cardiovascular disease. Bacterial endocarditis is a serious disease that settles in the endocardium and that can compromise the functioning of the heart muscle with serious risks, due to carelessness in relation to bacterial manifestation. The objective of this work is to analyze the main risks in relation to bacterial endocaditis in the hospital environment, as well as when the patient is submitted to some dental intervention. A search was carried out in the databases: Scielo and PubMed, using the following keywords: Bacterial endocarditis; hospital environment; risks, covering the period from 2000 to 2021. Bacterial endocarditis sets in when bacteria penetrate the bloodstream, migrate to the endocardium and adhere. Microorganisms begin to multiply and cause vegetation to appear, which are structures made up of cell debris, fibrin, platelets and bacteria, making it difficult for the heart to pump blood and leading to a risk of heart failure. It is concluded that bacterial endocarditis is a serious disease that can lead the patient to death, as it has a high risk of heart failure. For this reason, it is important to have a multidisciplinary team together with the dental surgeon in the hospital environment to develop therapeutic and prophylactic protocols for patients who need dental intervention.

show abstract

In-hospital metabolite changes in infective endocarditis—a longitudinal 1H NMR-based study

Cited by 4 publications

References 31 publications

Changes in the Serum Metabolome of Patients Treated With Broad-Spectrum Antibiotics

Changes in the Serum Metabolome of Patients Treated With Broad-Spectrum Antibiotics

Plasma levels of glucagon but not GLP-1 are elevated in response to inflammation in humans

Dental Intervention and the Risks of Bacterial Endocarditis in the Hospital Environment

Contact Info

Product

Resources

About